Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors

Anti-Cancer Drugs

Volumn 16, Issue 5, 2005, Pages 495-500

  Mercer, Stuart J ^a   Di Nicolantonio, Federica ^a   Knight, Louise A ^a   Gabriel, Francis G ^a   Whitehouse, Pauline A ^a   Sharma, Sanjay ^a   Fernando, Augusta ^a   Bhandari, Pradeep ^a   Somers, Shaw S ^a   Toh, Simon K ^a   Cree, Ian A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; Chemotherapy; Colon; Cyclooxygenase 2; Esophageal cancer; Irinotecan

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COX 2 GENE; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME REGULATION; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS TUMOR; FEMALE; GASTROINTESTINAL CARCINOMA; GENE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CYCLOOXYGENASE 2; ENZYME INDUCTION; FEMALE; FLUOROURACIL; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 21044445750     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200506000-00004     Document Type: Article

References (19)

1. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8:289-293.
2. Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 2002; 507:177-184.
3. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118:487-496.
4. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122:1800-1807.
5. Crosby CG, DuBois RN. The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opin Emerg Drugs 2003; 8: 1-7.
6. Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, et al. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus 2003; 16:177-186.
7. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-5282.
8. Moniotte S, Vaerman JL, Kockx MM, Larrouy D, Langin D, Noirhomme P, et al. Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol 2001; 33:2121-2133.
9. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, van der Holt B, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 2002; 16:833-839.
10. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Udereau R, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999; 45: 1148-1156.
11. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN, et al. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin E receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 2002; 62: 424-432.
12. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:research 0034.1-0034.11.
13. Applied Biosystems. ABI Prism 7700 Sequence Detection System User Bulletin 2. Relative Quantitation of Gene Expression (PIN 4303859B). Warrington: Applied Biosystems; 1997, pp. 11-15 (10/2001 update).
14. Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, et al. Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anticancer Drugs 2003; 14:397-403.
15. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000; 275:14838-14845.
16. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003; 278:37637-37647.
17. Yamaguchi K, Kazior A, Dannenberg AJ, Subbaramaiah K. Sn-38, a topoisomerase I inhibitor, blocks the activation of cyclooxygenase-2 transcription. Proc Am Ass Cancer Res 2003; 44:abstr 1599.
18. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002; 62:6323-6328.
19. Grösch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15:2742-2744.